AI-generated analysis. Always verify with the original filing.
On March 18, 2026, the District Court for the District of New Jersey filed an order delaying the bench trial between Catalyst Pharmaceuticals, Inc. and Hetero USA, Inc. from March 23, 2026 until May 18, 2026. The trial relates to the validity of the Company’s Orange Book-listed patents for FIRDAPSE® expiring in 2032, 2034, and 2037.